No Data
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $15
Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Express News | Abeona Therapeutics® Completes Pz-Cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
Abeona Therapeutics Price Target Maintained With a $18.00/Share by Cantor Fitzgerald
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
No Data
No Data